Transcription of Molecular Pathology/Molecular Diagnostics/ Genetic Testing
{{id}} {{{paragraph}}}
Example: bankruptcy
Molecular Pathology/Molecular Diagnostics/ Genetic Testing
UnitedHealthcare Medicare Advantage Policy Guideline Molecular Pathology/ Molecular diagnostics /. Genetic Testing Guideline Number: Approval Date: December 8, 2021 Terms and Conditions Table of Contents Page Related Medicare Advantage Policy Guidelines Policy Summary .. 1 Biomarkers in Cardiovascular Risk Assessment Applicable Codes .. 4 Blood Product Molecular Antigen Typing References .. 5. BRCA1 and BRCA2 Genetic Testing Guideline History/Revision Information .. 47. Clinical Diagnostic Laboratory Services Purpose .. 49. Terms and Conditions .. 49 Cytogenetic Studies (NCD ). Genetic Testing for Lynch Syndrome Human Tumor Stem Cell Drug Sensitivity Assays (NCD ). Molecular Diagnostic Infectious Disease Testing Molecular Pathology/ Genetic Testing Reported with Unlisted Codes Molecular Pathology Procedures for Human Leukocyte Antigen (HLA) Typing Pharmacogenomic Testing for Warfarin Response (NCD ).
Molecular Pathology/Molecular Diagnostics/Genetic Testing Page 3 of 49 UnitedHealthcare Medicare Advantage Policy Guideline Approved 01/12/2022 Proprietary Information of UnitedHealthcare.
Tags:
Information
Domain:
Source:
Link to this page:
Please notify us if you found a problem with this document: